Delivers real-time biopharma news and signals — powered by AI, curated for professionals.
Novo Nordisk has bounced back from recent setbacks with encouraging mid-stage results for its next-generation weight loss drug, amycretin. The Danish pharmaceutical giant released data from a Phase II trial involving 448 people with type 2 diabetes, demonstrating significant weight reduction and improved glucose control.
Eli Lilly's tirzepatide franchise is reshaping the landscape of pharmaceutical mega-blockbusters, with sales projections that dwarf previous industry giants. The rapid ascent of Mounjaro and Zepbound, along with the anticipated approval of orforglipron, marks a paradigm shift in the trajectory of blockbuster drug sales and market dominance.
AbbVie, a leading pharmaceutical company, has announced the launch of a new program aimed at fostering innovation in the Canadian biotech sector. The AbbVie Biotech Innovators Award, developed in collaboration with adMare BioInnovations, will provide early-stage biotechs in Quebec with valuable resources and expertise to accelerate their growth.
GE HealthCare has taken a significant step forward in medical imaging technology with the submission of its new photon-counting CT system, the Photonova Spectra, to the FDA for review. This development marks a pivotal moment in the evolution of computed tomography (CT) imaging, promising enhanced image quality and diagnostic capabilities.
Gilead Sciences, a major player in the pharmaceutical industry, has made a significant move to bolster its oncology pipeline by acquiring a preclinical cancer program from Swedish biotech Sprint Bioscience. The deal, announced on November 24, 2025, centers around a novel target known as TREX1 and could be worth up to $414 million.
In a rapidly evolving pharmaceutical landscape, the leadership of top executives plays a crucial role in steering companies towards success. Recent data from Glassdoor has shed light on how employees view their CEOs, revealing interesting correlations between approval ratings and company performance.
Ceribell, a leader in rapid electroencephalography (EEG) and brain monitoring solutions, has received FDA 510(k) clearance for its Clarity seizure-detection algorithm in neonates, marking a significant expansion of its technology into critical neonatal care.
Merck & Co. and its partner Kelun-Biotech have reported significant progress in the development of a potential first-line treatment for non-small cell lung cancer (NSCLC). The combination of Kelun's TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Merck's Keytruda has shown promising results in a late-stage clinical trial, potentially reshaping the landscape of lung cancer therapy.
Novo Nordisk, the Danish pharmaceutical giant, has announced significant progress in its amycretin development program, marking a major shift in the company's approach to diabetes treatment. The dual GLP-1 and amylin agonist, previously considered primarily for obesity, is now set to enter phase 3 trials for type 2 diabetes following impressive phase 2 results.
AstraZeneca's immunotherapy drug Imfinzi (durvalumab) has received FDA approval for the treatment of early-stage gastric and gastroesophageal junction (GEJ) cancers, marking a significant advancement in perioperative care for these patients. This latest approval establishes Imfinzi as the first immunotherapy to be used both before and after surgery in combination with chemotherapy for this patient population.
The Federal Trade Commission (FTC) has initiated legal proceedings to block Edwards Lifesciences' proposed $945 million acquisition of JenaValve, citing significant antitrust concerns in the transcatheter aortic valve replacement (TAVR) market. The case, which began with the FTC's opening statement presentation, highlights the potential creation of a monopoly in TAVR systems designed to treat aortic regurgitation.
Sarepta Therapeutics has received FDA approval to study an enhanced immunosuppressive regimen for its gene therapy Elevidys, aimed at addressing safety concerns that led to recent label restrictions. This development comes in the wake of significant setbacks for the Duchenne muscular dystrophy (DMD) treatment.
